The effects of Sarconesiopsis magellanica larvae (Diptera: Calliphoridae) excretions and secretions on fibroblasts

Pinilla, Yudi T.; Patarroyo, Manuel A.; Velandia, Myriam L.; Segura, Nidya Alexandra; Bello, Felio J.

doi:10.1016/j.actatropica.2014.11.003

Cited by 8 publications

(6 citation statements)

References 32 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, testing L. sericata hemolymph and saliva on the same cell line, [34] reported reduced toxicity to macrophages as in our study [34]. The evaluation of L. sericata and Sarconesiopsis magellanica ES effects on human lung cell line, MRC5, showed that the ES products of the ies had no effects on the survival rates at 10 µg/ml concentration, but they reduced the survival at 20 µg/ml [37]. The toxicity of ES seems to be a function of insect species, rearing methods, ES concentrations and storage conditions, as well as used cell lines.…”

Section: Discussionsupporting

confidence: 57%

The therapeutic effects of larval excretion/secretion of Lucilia sericata on Leishmania major under in vitro and in vivo conditions

Sherafati

Dayer

Ghaffarifar

2021

Preprint

View full text Add to dashboard Cite

Background Leishmaniasis is a neglected infectious disease caused by a kinetoplastid protozoan. The disease generally manifests as characteristic skin lesions. Due to the lack of definitive treatment and drugs without side effects, many studies have focused on natural compounds as promising drugs for its treatment. This study aimed to evaluate the effects of larval excretion/secretion products (ES) of Lucilia sericata in crude and fractionated forms on Leishmania parasites under both in vitro and in vivo conditions. Methods In vitro experiments involved evaluation of ES products on both promastigotes and amastigotes inside infected macrophages, whereas in vivo experiments included comparative treatments of Leishmanial lesions of mice using Eucerin-formulated ES products and glucantime. Results The IC50 values were 38.7 µg/ml, 47.6 µg/ml, 63.3 µg/ml, and 29.1 µg/ml for crude ES, over 10 kDa ES-fraction, under 10 kDa ES-fraction, and glucantime respectively. Significant differences were observed between viability percentages of promastigotes treated with crude ES and its fractions compared to negative control (p < 0.0001). Crude ES was more effective on amastigote than other two ES fractions at 300 µg/ml concentration. Macroscopic measurement of lesion sizes revealed that the reduction of lesion size in mice treated with crude ES followed quicker cascades of healing than in those treated with glucantime and fractionated ES. Conclusion The present study showed that larval ES of Lucilia sericata in both crude and fractionated forms are effective on both intracellular and extracellular forms of L. major. It also provided evidence that the larval ES exerts both topical and systemic therapeutic effects on leishmanial lesions of the model animal.

show abstract

Section: Discussionsupporting

confidence: 57%

The therapeutic effects of larval excretion/secretion of Lucilia sericata on Leishmania major under in vitro and in vivo conditions

Sherafati

Dayer

Ghaffarifar

2021

Preprint

View full text Add to dashboard Cite

show abstract

“…However, testing L. sericata hemolymph and saliva on the same cell line, Rahimi et al [41] reported lower toxicity to macrophages at a level comparable to that recorded in our study. Evaluating the effect of the ES derived from L. sericata and Sarconesiopsis magellanica on a human lung cell line (MRC5), Laverde-Paz et al [47] showed that it had no effect on cell survival rates at a low concentration (10 μg/ml), but was effective in reducing cell survival rates at a higher concentration (20 μg/ml). The toxicity of an ES seems to be a function of various factors including insect species, rearing methods, ES concentration and storage conditions, as well as the types of exposed cells.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic effects of Lucilia sericata larval excretion/secretion products on Leishmania major under in vitro and in vivo conditions

2022

View full text Add to dashboard Cite

Background Leishmaniasis is a neglected infectious disease caused by protozoa of the genus Leishmania. The disease generally manifests as characteristic skin lesions which require lengthy treatment with antimonial drugs that are often associated with adverse side effects. Therefore, a number of studies have focused on natural compounds as promising drugs for its treatment. This study aimed to evaluate the effects of larval excretion/secretion products (ES) of Lucilia sericata in crude and fractionated forms on Leishmania major, by using in vitro and in vivo models. Methods The in vitro experiments involved evaluation of ES on both promastigotes and macrophage-engulfed amastigotes, whereas the in vivo experiments included comparative treatments of skin lesions in L. major-infected mice with Eucerin-formulated ES and Glucantime. Results The half maximal inhibitory concentrations of the crude ES, > 10-kDa ES fraction, < 10-kDa ES fraction, and Glucantime were 38.7 μg/ml, 47.6 μg/ml, 63.3 μg/ml, and 29.1 μg/ml, respectively. Significant differences were observed between percentage viabilities of promastigotes treated with the crude ES and its fractions compared with the negative control (P < 0.0001). The crude ES was more effective on amastigotes than the two ES fractions at 300 μg/ml. The macroscopic measurements revealed that the reduction of lesion size in mice treated with the crude ES followed quicker cascades of healing than that of mice treated with Glucantime and the ES fractions. Conclusions The present study showed that the larval ES of L. sericata in both crude and fractionated forms are effective for both intracellular and extracellular forms of L. major. Also, the ES exert both topical and systemic effects on mice experimentally infected with L. major. Graphical abstract

show abstract

“…MTT assays were used to evaluate CC. 5 × 10 5 cell/well were seeded in 96-well plate for 24 h and eight, two-fold serial dilutions of sarconesin II (starting at 100 µM) were allowed to react with the cells for 24 h. 30% DMSO and medium were used as control [9]. 5 mg/mL of MTT reagent were incubated for 4 h at 37 °C and dissolved with 150 µL isopropanol.…”

Section: Methodsmentioning

confidence: 99%

“…AMPs have been identified in necrophagous flies’ salivary glands [8] and are important components of larval excretions and secretions (ES) during this phase of their biological development. Larval external digestion means that digestive enzymes such as serine and metalloproteinases, antibacterial molecules and other biochemicals produced by them are constituents of ES [9,10]. As flies live in an environment contaminated by pathogens’ oral ingestion, their innate defense system is activated, therefore inducing AMPs [11].…”

Section: Introductionmentioning

confidence: 99%

Sarconesin II, a New Antimicrobial Peptide Isolated from Sarconesiopsis magellanica Excretions and Secretions

et al. 2019

Self Cite

View full text Add to dashboard Cite

Antibiotic resistance is at dangerous levels and increasing worldwide. The search for new antimicrobial drugs to counteract this problem is a priority for health institutions and organizations, both globally and in individual countries. Sarconesiopsis magellanica blowfly larval excretions and secretions (ES) are an important source for isolating antimicrobial peptides (AMPs). This study aims to identify and characterize a new S. magellanica AMP. RP-HPLC was used to fractionate ES, using C18 columns, and their antimicrobial activity was evaluated. The peptide sequence of the fraction collected at 43.7 min was determined by mass spectrometry (MS). Fluorescence and electronic microscopy were used to evaluate the mechanism of action. Toxicity was tested on HeLa cells and human erythrocytes; physicochemical properties were evaluated. The molecule in the ES was characterized as sarconesin II and it showed activity against Gram-negative (Escherichia coli MG1655, Pseudomonas aeruginosa ATCC 27853, P. aeruginosa PA14) and Gram-positive (Staphylococcus aureus ATCC 29213, Micrococcus luteus A270) bacteria. The lowest minimum inhibitory concentration obtained was 1.9 μM for M. luteus A270; the AMP had no toxicity in any cells tested here and its action in bacterial membrane and DNA was confirmed. Sarconesin II was documented as a conserved domain of the ATP synthase protein belonging to the Fli-1 superfamily. The data reported here indicated that peptides could be alternative therapeutic candidates for use in infections against Gram-negative and Gram-positive bacteria and eventually as a new resource of compounds for combating multidrug-resistant bacteria.

show abstract

The effects of Sarconesiopsis magellanica larvae (Diptera: Calliphoridae) excretions and secretions on fibroblasts

Cited by 8 publications

References 32 publications

The therapeutic effects of larval excretion/secretion of Lucilia sericata on Leishmania major under in vitro and in vivo conditions

The therapeutic effects of larval excretion/secretion of Lucilia sericata on Leishmania major under in vitro and in vivo conditions

Therapeutic effects of Lucilia sericata larval excretion/secretion products on Leishmania major under in vitro and in vivo conditions

Sarconesin II, a New Antimicrobial Peptide Isolated from Sarconesiopsis magellanica Excretions and Secretions

Contact Info

Product

Resources

About